Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) FCF Margin (2021 - 2025)

Kiniksa Pharmaceuticals International's FCF Margin history spans 5 years, with the latest figure at 27.08% for Q4 2025.

  • For Q4 2025, FCF Margin rose 1183.0% year-over-year to 27.08%; the TTM value through Dec 2025 reached 20.35%, up 1435.0%, while the annual FY2025 figure was 20.35%, 1435.0% up from the prior year.
  • FCF Margin reached 27.08% in Q4 2025 per KNSA's latest filing, up from 18.25% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 62.57% in Q3 2022 to a low of 504.18% in Q2 2021.
  • Average FCF Margin over 5 years is 41.95%, with a median of 4.86% recorded in 2024.
  • Peak YoY movement for FCF Margin: soared 47517bps in 2022, then crashed -3726bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 102.08% in 2021, then surged by 108bps to 7.78% in 2022, then tumbled by -33bps to 5.21% in 2023, then soared by 193bps to 15.26% in 2024, then surged by 78bps to 27.08% in 2025.
  • Per Business Quant, the three most recent readings for KNSA's FCF Margin are 27.08% (Q4 2025), 18.25% (Q3 2025), and 17.81% (Q2 2025).